Trial Results Sample Clauses

The "Trial Results" clause defines how the outcomes and data from clinical or product trials are handled between the parties. It typically outlines who owns the trial data, how results may be shared or published, and any confidentiality or reporting obligations. For example, it may specify that one party must provide the other with access to raw data or that publication of results requires prior review. This clause ensures clarity regarding the use, disclosure, and ownership of trial findings, thereby preventing disputes and protecting proprietary information.
Trial Results. Each Party shall provide the other Parties ------------- with the right to review any contents of public disclosures, prepared by or otherwise under the control of such Party, to the extent that they are contractually permitted to do so, regarding the results of [*] pursuant to this Section 4.
View Source
Trial Results. ​ 5.1 All Trial Results, both positive and negative, as well as any intellectual and/or industrial property right(s) (including any Patent) resulting from the conduct of the Trial shall be the property of [***]. ​ 5.2 No Party may publish the Results, whether positive or negative, without the prior written consent of the other Party. ​
View Source
Trial Results. From January 1, 2010 through September 30, 2013, 112 smoking and health, ▇▇▇▇▇ Progeny and health-care cost recovery cases in which RJR Tobacco or B&W were defendants were tried, including 12 trials for cases where mistrials were declared in the original proceedings. Verdicts in favor of RJR Tobacco, B&W and, in some cases, RJR Tobacco, B&W and other defendants, were returned in 56 cases, including 21 mistrials, tried in Florida (52), Missouri (1) and West Virginia (4). Verdicts in favor of the plaintiffs were returned in 52 cases tried in Florida, one in Connecticut, and one in New York. Two cases in Florida were dismissed during trial. In the third quarter of 2013, five ▇▇▇▇▇ Progeny cases in which RJR Tobacco was a defendant were tried:
View Source
Trial Results. ▇▇▇▇▇▇▇▇ will also be entitled to publish with respect to the results of the PROSERA Phase 3 Study and any associated pre-clinical research associated with Licensed Compound or Licensed Products, in its ordinary course, subject to prior review, comment and approval (not to be unreasonably withheld, delayed or conditioned) by ▇▇▇▇▇▇ (with the proposed publication to be provided to Chiesi not less than 30 days prior to intended submission). Notwithstanding anything in this Agreement to the contrary, each Party will be entitled to disclose, without the consent of or any notification to the other Party, any pharmacovigilance information originating from itself, its Affiliates, and the other Party with Regulatory Authorities, investigators, ethical committees and internal review boards, and any other Third Parties that have a need to know such information according to each Party’s risk management and adverse event reporting requirements provided that such disclosure complies with applicable Law.
View Source
Trial Results. “TRS”) At the end of the Study, approximately twelve (12) months after the last Study Subject last visit for the overall Study, Sponsor will develop a summary of the trial results to be shared with the Study Subjects. The TRS will translate the technical results into easy to understand language. Sponsor will consult with the Site to confirm the number of copies required and translations. Based on the information provided by the Site, Sponsor, directly or through a third party vendor, will mail the TRS to the Site or provide the link to the public website where the TRS will be located. The Site or designee will be responsible to mail the TRS or provide the link to the Study Subjects or provide it to the Study Subjects directly if applicable.
View Source
Trial Results. After analysis of Trial Data from all sites is complete, SPONSOR will provide Principal Investigator and Institution with a summary of the overall results of the Trial. If the results show that Human Subject safety could be adversely affected, SPONSOR, in consultation with the IRB/IEC as appropriate, will cooperate with Principal Investigator and Institution to ensure that those results are appropriately communicated to the Human Subjects by Principal Investigator and/or Institution during the 2 year period following the close of the Trial.
View Source

Related to Trial Results

  • Results Revvity Omics will return the results of the Sequencing Test to the Ordering Provider via secure e-mail.

  • ADVERTISING RESULTS The prior written approval of the Commissioner is required in order for results of the Bid to be used by the Contractor as part of any commercial advertising. The Contractor shall also obtain the prior written approval of the Commissioner relative to the Bid or Contract for press or other media releases.

  • Ownership of Results Any interest of Contractor or its subcontractors, in the Deliverables, including any drawings, plans, specifications, blueprints, studies, reports, memoranda, computation sheets, computer files and media or other documents prepared by Contractor or its subcontractors for the purposes of this Agreement, shall become the property of and will be transmitted to City. However, unless expressly prohibited elsewhere in this Agreement, Contractor may retain and use copies for reference and as documentation of its experience and capabilities.

  • Publication of Results The National Aeronautics and Space Act (51 U.S.C. § 20112) requires NASA to provide for the widest practicable and appropriate dissemination of information concerning its activities and the results thereof. As such, NASA may publish unclassified and non-Proprietary Data resulting from work performed under this Agreement. The Parties will coordinate publication of results allowing a reasonable time to review and comment.

  • Notification of Results Within 10 days after satisfactory inspection and/or testing of Interconnection Facilities built by the Interconnection Customer (including, if applicable, inspection and/or testing after correction of defects or failures), the Interconnected Transmission Owner shall confirm in writing to the Interconnection Customer and Transmission Provider that the successfully inspected and tested facilities are acceptable for energization.